SOMAÍ products are available in Germany: innovative Oral Solutions
SOMAÍ acquired RPK Biopharma: enhanced capabilities, non-irradiated cannabis cultivars, and Cookies strains
SOMAÍ enters the UK market with the distribution deal with Grow Pharma; the first products are to hit the shelves
SOMAÍ raised €4 Million
In-vivo and in-vitro studies International conferences: Australia, Thailand, Portugal, and more
March went fantastic, and we want to share the latest achievements and plans for the following month. Our first line of products is now accessible to the patients as we have made the first step in conquering the global medicinal cannabis market.
In March, SOMAÍ Oral Solutions became available in Germany on prescription for patients at Grünhorn Pharmacy and through the largest cannabis network canymed GmbH for pharmacies across Germany. With the future development of German regulations for extracts, we hope to soon make even more innovative products from our broad range accessible to physicians and patients.
This product line is only the beginning of our global launch of the broadest medicinal cannabis portfolio, including Oral Solution Proprietary Formulations, Oral Spray lines, Soft Gel Capsules, Inhalation Oil cartridges, and many more to meet the evolving patients’ needs. At SOMAÍ Pharmaceuticals, our primary goal is to revolutionize global medicinal cannabis markets by delivering exceptional products that cater to the diverse needs of patients.
One of the main highlights of this month is SOMAÍ’s acquisition of RPK Biopharma (Holigen). The company we purchased has a 25,000-square-foot indoor EU-GMP-certified grow facility in Sintra dedicated to the cultivation of high-THC premium cannabis flower. This strategic step not only allows us to cover the market needs of premium-quality, non-irradiated cannabis cultivars but also to provide patients with high-in-demand Cookies strains. This investment will significantly accelerate SOMAÍ’s global leadership, improving our Company’s ability to deliver a ground-breaking differentiated cannabinoid-containing product portfolio to meet patients’ needs worldwide. The acquisition enhances SOMAÍ’s capacity with best-in-class cultivation, manufacturing, and distribution assets, making it one of the few verticals in the EU able to cater to the diverse needs of fast-growing European cannabis markets.
In March, SOMAÍ Pharmaceuticals introduced the UK to the most complete cannabis-based product portfolio following a distribution deal with GROW® Pharma . Under the two-year agreement, SOMAÍ will create access to its differentiated cannabinoid-containing product portfolio for all the UK-based medical cannabis-prescribing clinics and doctors, utilizing Grow Pharma’s extensive distribution network.
Following the momentum, SOMAÍ Pharmaceuticals has raised €4 Million, further expanding our capabilities. George Bellow, co-founder and Managing Partner: “Today marks another significant milestone in our journey as we proudly announce the successful raising of an additional €4 million investment. This reaffirms our commitment to both grow organically as well as mergers and acquisitions.” At SOMAÍ, we believe investing in Research & Development is critical to moving the industry forward and providing better help for patients with various health conditions. Our team continues to create new innovative formulations that will completely redefine the landscape of the medicinal cannabis sector. Additionally, we are currently running several pharmacokinetic, in-vivo and in-vitro studies generating additional data for our products.
SOMAÍ Pharmaceuticals was very active in the global arena, participating in events across the globe: Thailand, Australia, and Portugal. At the end of February, we attended the Cannabis Business Asia-Pacific 2024, which took place in Bangkok, Thailand. Michael Sassano took the main stage and shared the company’s vision of creating next-generation products that consider the market’s golden standards. Later on, we were honored to be the official Gala Dinner Partner at the ACannabis Conference in Melbourne, Australia, and to meet many talented, passionate Australian doctors, pharmacists, and industry professionals who are moving the industry forward. At the end of March, SOMAÍ sponsored the Third National Conference of Medicinal Cannabis, organized by the OPCM—Portuguese Observatory of Medicinal Cannabis in Coimbra, Portugal.
SOMAÍ stands at the frontline of scientific research and development and understands the importance of moving the industry forward to provide more patients with a better, healthier life.
April 2024
In April, our global reach will expand further. From the initial launch in Germany, we will have our first line of Oral Solutions with different THC and CBD concentrations available for patients in Australian and UK markets. SOMAÍ has over 86 stabilized extracted SKUs and is continuously manufacturing new advanced product lines monthly for cannabis markets worldwide. Our next-generation Oral Solution line, produced in March, is ready to be shipped in the upcoming month. Our products cover all patients’ evolving needs, from premium-quality Cookies cannabis flower to innovative finished dosage forms. Our formulations are crafted with precision, purity, and taste and represent our commitment to providing patients with tailored medicinal cannabis solutions. Our robust and improved-tasting product portfolio is set to evolve with proprietary terpene taste profiles, promising to revolutionize existing product lines.
In April, the SOMAÍ team will be attending the International Cannabis Business Conference InternationalCBC, which will take place on the 16-17 April in Berlin. If you’re interested in exploring potential collaborations with SOMAÍ Pharmaceuticals, don’t hesitate to schedule a meeting by reaching out to hello@somaipharma.eu.
Get ready for the launch of our latest, more advanced product lines every month – stay tuned for the excitement! We’re crafting products for today, tomorrow, and beyond.
